Reports suggest that angiosarcomas can express PD-L1, and patients have shown improved prognosis following PD-L1 inhibitor pembrolizumab treatment.[15] Therefore, immunotherapy could be a promising new therapy for angiosarcomas. The gene discussed is CD274; the disease is angiosarcoma.